Lack of alkaline phosphatase activity predicts meningioma recurrence

American Journal of Clinical Pathology

Volumn 124, Issue 2, 2005, Pages 252-258

  Bouvier, Corinne ^a   Liprandi, Agnès ^a   Colin, Carole ^a   Giorgi, Roch ^a   Quilichini, Benoit ^a   Metellus, Philippe ^a   Figarella Branger, Dominique ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

1p Deletion; Alkaline phosphatase; Cytogenetics; Meningiomas; Recurrence

Indexed keywords

ALKALINE PHOSPHATASE; KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURGERY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MENINGIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR RECURRENCE;

EID: 23044493370     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/482AWA3U8DJUEXWU     Document Type: Article

References (26)

1. Louis DN, Scheithauer BW, Badka H, et al. Meningiomas. In: Kleihues P, Cavenee WK, eds. Pathology and Genetics: Tumours of the Nervous System. Lyon, France: IARC Press; 2000:176-184. World Health Organization Classification of Tumours.
2. Figarella-Branger D, Bouvier-Labit C, Liprandi A, et al. Prognostic factors in meningiomas. Ann Pathol. 2000;20:438-447.
3. Hsu DW, Efird JT, Hedley-Whyte ET. MIB-1 (Ki-67) index and transforming growth factor-alpha (TGF alpha) immunoreactivity are significant prognostic predictors for meningiomas. Neuropathol Appl Neurobiol. 1998;24:441-452.
4. Ayerbe J, Lobato RD, de la Cruz J, et al. Risk factors predicting recurrence in patients operated on for intracranial meningioma: a multivariate analysis. Acta Neurochir (Wien). 1999;141:921-932.
5. Yamasaki F, Yoshioka H, Hama S, et al. Recurrence of meningiomas. Cancer. 2000;89:1102-1110.
6. Simon M, von Deimling A, Larson JJ, et al. Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. Cancer Res. 1995;55:4696-4701.
7. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA. 1997;94:14719-14724.
8. Lamszus K, Kluwe L, Matschke J, et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet. 1999;110:103-110.
9. Leone PE, Bello MJ, de Campos JM, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene. 1999;18:2231-2239.
10. Dezamis E, Sanson M. The molecular genetics of meningiomas and genotypic/phenotypic correlations. Rev Neurol (Paris). 2003;159:727-738.
11. Bello MJ, de Campos JM, Kusak ME, et al. Allelic loss at 1p is associated with tumor progression of meningiomas. Genes Chromosomes Cancer. 1994;9:296-298.
12. Lindblom A, Ruttledge M, Collins VP, et al. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer. 1994;56:354-357.
13. Sulman EP, Dumanski JP, White PS, et al. Identification of a consistent region of allelic loss on 1p32 in meningiomas: correlation with increased morbidity. Cancer Res. 1998;58:3226-3230.
14. Ishino S, Hashimoto N, Fushiki S, et al. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization. Cancer. 1998;83:360-366.
15. Cai DX, Banerjee R, Scheithauer BW, et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol. 2001;60:628-636.
16. Ketter R, Henn W, Niedermayer I, et al. Predictive value of progression-associated chromosomal aberrations for the prognosis of meningiomas: a retrospective study of 198 cases. J Neurosurg. 2001;95:601-607.
17. Lopez-Gines C, Cerda-Nicolas M, Gil-Benso R, et al. Loss of 1p in recurrent meningiomas: a comparative study in successive recurrences by cytogenetics and fluorescence in situ hybridization. Cancer Genet Cytogenet. 2001;125:119-124.
18. Zucchini C, Bianchini M, Valvassori L, et al. Identification of candidate genes involved in the reversal of malignant phenotype of osteosarcoma cells transfected with the liver/bone/kidney alkaline phosphatase gene. Bone. 2004;34:672-679.
19. Timperley WR, Warnes TW. Alkaline phosphatase in meningiomas. Cancer. 1970;26:100-103.
20. Murakami M, Kuratsu J, Mihara Y, et al. Histochemical study of alkaline phosphatase in primary human brain tumors: diagnostic implications for meningiomas and neurinomas. Neurosurgery. 1993;32:180-184.
21. Niedermayer I, Feiden W, Henn W, et al. Loss of alkaline phosphatase activity in meningiomas: a rapid histochemical technique indicating progression-associated deletion of a putative tumor suppressor gene on the distal part of the short arm of chromosome 1. J Neuropathol Exp Neurol. 1997;56:879-886.
22. Swallow DM, Povey S, Parkar M, et al. Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1. Ann Hum Genet. 1986;50(pt 3):229-235.
23. Muller P, Henn W, Niedermayer I, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res. 1999;5:3569-3577.
24. Bouvier-Labit C, Chinot O, Ochi C, et al. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol. 1998;24:381-388.
25. Dutrillaux B, Lejeune J. A new technic of analysis of the human karyotype [in French]. C R Acad Sci Hebd Seances Acad Sci D. 1971;272:2638-2640.
26. Lamszus K. Meningioma pathology, genetics and biology. J Neuropathol Exp Neurol. 2004;63:275-286.